TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologic or cytologic diagnosis of primary or metastatic epithelial cancer or sarcoma located in the head and neck area, lung, abdomen or pelvis.~* Tumors must have an overall dimension greater than 24 cm2 (bidimensional) with one dimensions \>6 cm, by x-ray, CT/MRI scan or clinical exam.~* Age \>18~* Karnofsky \> 70 with life expectancy \>3 months.~* Patients may not begin new hormone therapy within 2 weeks of initiation of protocol treatment.~* No planned initiation of hormone therapy within 2 weeks of protocol therapy~* Adequate bone marrow function: Hb \> 9, white blood cell count (WBC) \> 2,000. Hepatic function \< 3x upper limit of laboratory normal values.~* Laboratory studies will be obtained within 2 weeks prior to randomization.~* Patients with metastatic sites of disease including brain are eligible provided that life expectancy is \> 3 months.~Exclusion Criteria:~* Hematologic-related tumors.~* Tumors overlying critical central nervous system structures including spinal cord, eye or brainstem or require treatment portals over these vital structures.~* Central nervous system tumors~* Evidence of other primary malignancy except for carcinoma in situ of cervix or skin cancer excluding melanoma unless disease free for 2 years prior to randomization~* Patients with spinal cord compression.~* Prior radiation to treatment field.~* Concomitant chemotherapy or chemotherapy within past 2 weeks. Planned initiation of chemotherapy within 2 weeks of completing protocol treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: ACTIVE_COMPARATOR): Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
- Treatment Group-2 (Type: ACTIVE_COMPARATOR): Treatment Group 2-15 treatments with standard radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant must have been actively participating in the double-blind study, BPS-314d-MR-PAH-302 (NCT01908699), when the Sponsor concluded that study.~2. In the Investigator's opinion, participant must be competent to understand the information given in the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved informed consent form (ICF) and must sign the form prior to the initiation of any study procedures.~3. Women of child-bearing potential (defined as less than 1 year post-menopausal and not surgically sterile) must be practicing abstinence or using 2 highly-effective methods of contraception (defined as a method of birth control that results in a low failure rate \[that is, less than 1% per year, such as approved hormonal contraceptives, barrier methods (such as a condom or diaphragm) used with a spermicide or an intrauterine device\]). Participant must have a negative pregnancy test at the BPS-314d-MR-PAH-302 EOS Visit / BPS-314d-MR-PAH-303 Enrollment Visit.~4. Participant must be willing and able to comply with study requirements and restrictions.~Exclusion Criteria:~1. Participant is pregnant or lactating.~2. Participant is scheduled to receive another investigational drug, device, or therapy during the course of the study.~3. Participant is taking or intends to take any prostacyclin / prostacyclin (IP) analog or IP receptor agonist (except for treprostinil, inhaled \[Tyvaso®\]).~4. Participant has any other clinically significant illness or other reason that, in the opinion of the Investigator, might put the participant at risk of harm during the study or might adversely affect the interpretation of the study data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Esuberaprost (Type: EXPERIMENTAL): Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
- Placebo/Esuberaprost (Type: PLACEBO_COMPARATOR): Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Minocycline Therapy for Management of Adverse Radiation Effects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 18 - 90 years~* Males and females.~* Patients must have undergone cranial radiosurgery.~* MRI evidence supporting the diagnosis of ARE and/or surgical biopsy evidence of necrosis without tumor at ≤2 months before study entry.~* Karnofsky performance status of ≥60,~* With or without evidence of progressive neurologic signs or symptoms appropriate to the location of the ARE, and no previous bevacizumab therapy.~* With or without previous chemotherapy for their tumor.~* Routine laboratory study results with bilirubin ≤1.5 times the upper limit of normal, aspartate aminotransferase and/or alanine aminotransferase \<2.5 times the upper limit of normal, creatinine \<2.0 times the upper limit of normal.~* Patients with a history of seizures will be required to be receiving anticonvulsant therapy and to be seizure-free for ≥1 week before study.~Exclusion Criteria:~* Significant mass effect requiring resection (as assessed by a clinical neurosurgeon)~* Known hypersensitivity to tetracyclines~* Women of childbearing age must be non-lactating and have a negative urine pregnancy test (adequate birth control includes use of intra uterine device, or a barrier method, e.g. condom, diaphragm). The results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues, having potentially toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. Therefore pregnant women will not be allowed to participate in this study~* Female subjects on oral contraceptives~* Contraindication to undergo MRI~* Significant cardiopulmonary, renal or neurological co-morbidities~* Current diagnosis of major depression, substance abuse, or other psychiatric disorders;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: EXPERIMENTAL): oral Minocycline 100 mg twice a day for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients: 18 to 59 years~2. Women of childbearing potential must agree to use a medically accepted means of contraception for the duration of the study~3. DSM IV MINI diagnosis of major depressive episode (MDD), unipolar or bipolar~4. Pretreatment 24-item Hamilton Rating Scale for Depression score \> 21~5. ECT is clinically indicated~6. Patient has the capacity to provide informed consent.~Exclusion Criteria:~1. DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or mental retardation~2. Current primary diagnosis of anxiety disorder, obsessive- compulsive disorder, or eating disorder that precedes the onset of the current episode of depression~3. Current diagnosis of delirium, dementia, or amnestic disorder~4. Baseline Mini Mental State Exam (MMSE) score \< 24 and a total score falling two standard deviations below the age- and education-adjusted mean~5. Any active general medical condition or CNS disease which can affect cognition or response to treatment~6. Current (within the past three months) diagnosis of active substance dependence, or active substance abuse within the past week~7. Lifetime history of ketamine or PCP abuse or dependence~8. ECT within three months~9. The presence of any known or suspected contraindication to methohexital or ketamine including but not limited to known allergic reactions to these agents, uncontrolled hypertension arrhythmia severe coronary artery disease and porphyria~10. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
- Methohexital (Type: ACTIVE_COMPARATOR): Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological proof of neuroendocrine cancers (including small cell cancers of any site \[including lung\] or poorly differentiated neuroendocrine cancers of the lung with (unidimensionally) measurable disease as per the RECIST criteria~* Chemoresistant or chemosensitive disease~* Patients must have received treatment with at least one but not more than 2 prior chemotherapy regimens, including one regimen containing a platinum agent~* Radiation therapy must have completed their radiation at least 14 days prior to being registered for protocol therapy, and toxicities due to radiation must have recovered to \< grade 1 or baseline prior to registration~* Negative pregnancy test~Exclusion Criteria:~* No clinically significant infections as judged by the treating investigator~* No symptomatic CNS metastasis~* No radiation to \> 25% of the marrow containing spaces~* No previous treatment with pemetrexed~* No uncontrolled pleural effusions~* No current breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PLAY LONG: The Effect of Sports and Recreation Participation for Young chiLdren With physicAl disabilitY

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At the time of enrollment, the child must be between the ages of 5 and 10 and be participating in an adapted sports and recreation program.~* At the time of enrollment, the parent must have a child between the ages of 5 and 10, who is participating in an adapted sports and recreation program.~* Children and parents who are enrolled in the study will continue to participate in the study for 10 years.~Exclusion Criteria:~* Children who are younger than 5 or older than 10 will not be entered into the study, nor will parents whose children are younger than 5 or older than 10 be entered into the study. .~* Individuals who do not read and write in English will be excluded from the study.~* Children who are wards of the state, or in foster care will be excluded from the study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Children in Sports and Rec (Type: None): Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
- Comparison Children (Type: None): Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 2-17~* Presence of more than 15 eosinophils per hpf on original endoscopy and less than 5 eosinophils/hpf on the most recent endoscopy~* Concurrent PPI for 1 month at 1-2mg/kg/dose prior to endoscopy or have a negative pH study~* English speaking~* Ability to undergo a follow up endoscopy between 12 and 13 weeks after the start of the study~* Procurement of written informed consent signed by the subject's legal guardian and study investigator (s) and subject assent.~Exclusion Criteria:~* Subjects with eosinophils in stomach and duodenum on original endoscopy.~* Subjects requiring oral prednisone within 1 month of current endoscopy.~* Subjects with diagnosis of other co-morbid diseases such as heart disease, renal disease, autoimmune disease, an immunodeficiency, diabetes, phenylketonuria, or thyroid disease.~* Subjects using Montelukast within one month of current endoscopy~* Subjects with concurrent use of phenobarbital or rifampin

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast 10 mg/day (Type: EXPERIMENTAL): Subjects will receive two 5mg tablets of Montelukast/day.
- Montelukast 5mg/day (Type: EXPERIMENTAL): Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
- placebo (Type: PLACEBO_COMPARATOR): Subjects will receive two placebo tablets per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with cervical dystonia/spasmodic torticollis for at least 18 months~* Successfully treated previously with botulinum toxin type A~Exclusion Criteria:~* Breast feeding, pregnant, or could become pregnant~* Surgery or spinal cord stimulation for cervical dystonia~* Previous injections of phenol, alcohol for cervical dystonia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® (Type: EXPERIMENTAL): Botulinum toxin type A (BOTOX®)
- Dysport® (Type: ACTIVE_COMPARATOR): Botulinum toxin type A (Dysport®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Is 18-75 years of age at Screening~2. Has ALS symptom onset within 2 years prior to Screening~3. Has forced vital capacity (FVC) no higher than 60% at screening~4. If taking riluzole, is on a stable dose for 4 weeks before Screening~Exclusion Criteria:~1. Has tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation of any type~2. Has used any medication within a time period not allowed per protocol~3. Has history of Type 1 or Type 2 diabetes mellitus, or any clinically significant infection~4. Used edaravone less than 1 week before Screening~5. Received any stem cell replacement therapy~6. Used steroids within a time period not allowed per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Treatment Period Acthar (Type: EXPERIMENTAL): Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39.
- Arm B: Treatment Period Placebo (Type: PLACEBO_COMPARATOR): Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39.
- Arm C: Extension Period Acthar-Acthar (Type: EXPERIMENTAL): Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
- Arm D: Extension Period Placebo-Acthar (Type: EXPERIMENTAL): Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years old~* Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease~* ECOG performance status of 0, 1, or 2~* No prior systemic chemotherapy for the treatment of SCLC~Exclusion Criteria:~- Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMGN901 with carboplatin and etoposide (Type: EXPERIMENTAL): Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
- Carboplatin and Etoposide (Type: ACTIVE_COMPARATOR): Patients will receive Carboplatin and etoposide for up to 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dräger COVID-19 Antigen Test Clinical Performance Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must require SARS-CoV-2 testing for the following reasons:~  * COVID-19 symptoms (Fever, cough and/or sore throat, fatigue/ general feeling of weakness, loss of sense of smell and/or taste, shortness of breath, muscle stiffness/ body aches, head cold/ running nose, etc.) on the day of testing, or~ * Known or suspected exposure to SARS-CoV-2 (contact persons etc.), or~ * Member of a group of high risk of exposure such as healthcare workers etc., or~ * Require screening for any other reason, e.g. doctor's orders, hygiene directive etc.~* Participant must be of legal age and must be able to understand the procedure and letter of consent.~Exclusion Criteria:~* Patients younger than 18 years old are excluded from the study.~* Pregnant or breastfeeding patients are excluded from the study.~* Patients unable to provide written informed consent are excluded.~* Patients with bleeding disorder are excluded from the study as a precaution.~* Hospitalized patients/inpatients are excluded.~* Application of nasal spray within 15 min prior to testing.~* Participants with symptoms on the day of testing are excluded, if any of their symptoms started more than 14 days prior to testing.~* Asymptomatic participants are excluded, if they experienced any symptoms in the 14 days prior to testing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symptomatic (Type: OTHER): Collection of specimens from symptomatic COVID-19 positive participants
- Asymptomatic (Type: OTHER): Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues